Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland.
about
Prevention of vertical transmission of HIV-1 in resource-limited settingsAntiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant womenAssociation between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studiesIs protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysisAntiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic ReviewPregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trialAsking the right questions: developing evidence-based strategies for treating HIV in women and childrenGlobal report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and IrMultiple Overimputation to Address Missing Data and Measurement Error: Application to HIV Treatment During Pregnancy and Pregnancy OutcomesReducing stillbirths: prevention and management of medical disorders and infections during pregnancy.Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data.Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conceptionVaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocolBirth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infants.Predictors of adverse pregnancy outcomes in women infected with HIV in Latin America and the Caribbean: a cohort study.Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in BotswanaHighly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.Mitochondrial toxicity in human pregnancy: an update on clinical and experimental approaches in the last 10 years.Antiretroviral regimens in pregnancy and breast-feeding in Botswana.Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women.Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in BotswanaMode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe.Managing HIV in pregnancy in a community-based sexual health clinic: a decade in review.HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restrictionHIV-Associated Tuberculosis in the Newborn and Young Infant.Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infantsLow birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon.Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational studyRisk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.Mother-to-child transmission of human immunodeficiency virus in aten years periodRisk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.Accuracy of ICD-9-CM coding to identify small for gestational age newbornsInsufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe.Combination antiretroviral use and preterm birth.Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana
P2860
Q22241479-213765A6-EA8A-4D6C-B719-6AD662A08438Q24236763-279547B5-2815-4D8A-BB74-9993585D7FD9Q26785714-23788521-ED86-4A2F-9344-D2001587143FQ28066290-96685504-F58A-40C8-88A2-7BEE7D32C90DQ28080543-11ACBCA0-720F-47D8-81FD-0BB60C52A312Q28483723-130D0783-3F98-4D22-9F61-53F3E69603BEQ28743488-EAD60F4C-743F-4B92-A517-42895770E33CQ30227236-FFEF3EC1-3C87-450B-A681-CB82F0D9D20AQ30244368-7548FFE1-8A06-4979-9DE7-26EFB0E2A37EQ30987069-B5729E4D-AE40-4F65-A448-3FA5DA133FE5Q31043161-E414F95C-1D04-4467-9F5A-AD8A843E6C29Q31070972-FB41FDE2-F2B2-4153-A9C3-FECB107B1F32Q33441799-0C073C4F-C992-4F2D-9E34-FC7BCDD6AD76Q33667399-E5B35CE9-3659-47BD-91F0-059E43687193Q33830084-EFF80EC0-9D18-427B-8A4A-DA6DFB645AEDQ33916922-F9349F03-4FB3-4EDE-A453-46631BA88331Q34104017-A6BAB4DD-BFBB-4C37-BC0E-FFDEFE00E9ADQ34146634-540F100C-52BB-4150-8D09-FA3DA6B1507AQ34158407-661823D8-DC85-47ED-BDDF-EBCA883C35E2Q34181776-2A0FB285-42D1-4994-9FC5-C56A32363F45Q34306176-49F9CB67-6B27-4CEA-AFB9-A001EE2C0DBBQ34348392-B98B73D5-DD8D-4321-B7FF-3EF73560FC19Q34395082-555C0BDB-920E-45CB-A507-DB67E7DFC9EFQ34408889-DBE3027A-11B1-4B84-80F6-94971442E80BQ34500824-62F9ED4E-6B90-4B5F-A18B-DA9B44C20F0AQ34615517-FD4E3E1F-88B5-41D0-96C6-1845F19FC2ADQ34645470-DFF54A25-5516-45E7-94F9-267D959340CFQ34687799-2FA55297-7E19-4F1B-BC25-7019DC6588F2Q34877096-28AF07C3-9442-40BA-BC5B-F770292304F9Q35084426-BA445B22-1FFC-4330-883C-BF5A2043BF6AQ35140240-32C264B8-64DD-429A-885E-5CAE5E098719Q35184921-4BFBB9A3-91F4-4E99-B2FB-A6456A1EA15FQ35551457-7D976DB6-0D01-4BA6-B9BF-6F0E944B33E7Q35639429-2F17A567-C4E0-4AD0-A8DE-284C5CF1792DQ35691443-C128FC39-8D5B-4180-96FB-654738134C5FQ35738687-193C411D-ED0F-434F-9702-EDCA0616DDC8Q35945479-D81804DC-F538-4E3B-A132-48396EBE7662Q36193260-4BE086C0-D00A-4CF5-BC95-491CF5F8CD77Q36547343-B1464450-9CA5-4BB9-8F5C-58DCAA1BDCFAQ36619600-A710A1F9-E5D4-40BB-A128-E00C26463EC3
P2860
Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@en
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@nl
type
label
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@en
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@nl
prefLabel
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@en
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@nl
P2093
P1433
P1476
Antiretroviral therapy and pre ...... he United Kingdom and Ireland.
@en
P2093
Catherine S Peckham
Claire L Townsend
Mario Cortina-Borja
P304
P356
10.1097/QAD.0B013E328133884B
P407
P50
P577
2007-05-01T00:00:00Z